Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients

• Published in: Scientific reports Vol. 14; no. 1; pp. 27491 - 11
• Main Authors: Dai, Jhih-Wei, Lin, Yuan, Li, Xiu-Wei, Tseng, Chin-Ju, Tsai, Ming-Lung, Yang, Ning-I, Hung, Ming-Jui, Chen, Tien-Hsing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.11.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/163; 692/308; 692/4019; Aged; Antidiabetics; Asian People; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cardiovascular outcomes; Cerebral infarction; Creatinine; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Dialysis; Dulaglutide; Female; Glomerular Filtration Rate; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - analogs & derivatives; Glucagon-Like Peptides - therapeutic use; Health risks; Humanities and Social Sciences; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Immunoglobulin Fc Fragments - adverse effects; Immunoglobulin Fc Fragments - therapeutic use; Ischemia; Kidneys; Liraglutide; Liraglutide - adverse effects; Liraglutide - therapeutic use; Male; Middle Aged; multidisciplinary; Myocardial infarction; Patients; Recombinant Fusion Proteins - therapeutic use; Renal outcomes; Retrospective Studies; Science; Science (multidisciplinary); Treatment Outcome; Cardiovascular outcomes; Renal outcomes; Dulaglutide; Liraglutide
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-79255-9

Given the limited head-to-head comparison of cardiovascular and renal outcomes between liraglutide and dulaglutide, our study aimed to investigate the clinical outcomes between dulaglutide and liraglutide in a real-world setting. In this new-user design, comparative and retrospective cohort study, patients with type 2 diabetes mellitus with prescription for GLP-1RAs from January 1, 2016 to December 31, 2022 ( n  = 8,278) were included. Primary outcome was composite cardiovascular outcomes which was composed of cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke. The composite renal outcome was also interested, including new macroalbuminuria, doubling of serum creatinine, worsening of estimated glomerular filtration rate (eGFR), and progression to dialysis. A total of 3,210 subjects receiving liraglutide and 5,068 subjects receiving dulaglutide were identified. In the adjusted cohort by applying inverse probability of treatment weighting, the incidence of composite cardiovascular outcomes was 18.4 and 18.7 events per 1000 person-years in the liraglutide and dulaglutide groups, respectively. The risk of cardiovascular outcomes did not significantly differ between groups (hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.85–1.15). Moreover, the risk of composite renal outcomes was also comparable between groups (subdistribution HR 1.07, 95% CI 0.995–1.16). Liraglutide and dulaglutide demonstrated comparable cardiovascular and renal outcomes in a real-world setting.